NCT00666705

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.

Detailed description

Drug interaction study

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Maraviroc	300 milligrams(mg) every 12 hours Days 6-11
DRUG	Maraviroc	Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
DRUG	Raltegravir	Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
DRUG	Raltegravir	400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5

Timeline

• Start date: 2008-02-01
• Primary completion: 2008-03-01
• Completion: 2008-03-01
• First posted: 2008-04-25
• Last updated: 2013-01-25
• Results posted: 2009-06-04

Locations

1 site across 1 country: United States